Agreement with ImmunoVaccine Technologies

06/08/2009

GB00B39J5N63

                             Scancell Holdings Plc                             

                    (`Scancell Holdings' or the `Company')                     

                     Scancell Partners With ImmunoVaccine                      

                 Technologies to Advance DNA Vaccine Delivery                  

Scancell Holdings Plc, the parent company of Scancell Limited (`Scancell'), the
developer of therapeutic cancer vaccines based on its patented ImmunoBody®
platform, is pleased to announce it has signed a research agreement with
ImmunoVaccine Technologies Inc. (`IVT'), a Canadian vaccine development company
to explore the potential of using IVT's DepoVaxâ„¢ delivery system for Scancell's
novel ImmunoBody® DNA vaccines.

DNA-based vaccines such as those being developed by Scancell have gained
popularity due to promising results reported in the clinic, their relative ease
of manufacture and potential for enhanced stability. There is currently a need
for simple alternative methods of delivering DNA vaccines.

DepoVaxâ„¢ is a vaccine-enhancement and delivery platform comprised of liposomes,
adjuvants and oil. DepoVaxâ„¢ enhances the immunogenicity of antigens in general,
and can be used to dramatically enhance the delivery of polynucleotide-based
antigens and SiRNA to lymph nodes. IVT has proven its scale-up capabilities at
a contract manufacturing plant, making DepoVaxâ„¢ amenable to commercialisation.

Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® technology
platform. Scancell's first cancer vaccine SCIB1 is being developed for the
treatment of melanoma and will enter clinical trials using electroporation
technology in early 2010.

David Evans, chairman of Scancell, commented:

"IVT's DepoVaxâ„¢ represents a potentially attractive future delivery system for
our ImmunoBody® DNA vaccines, especially those for certain infectious diseases
where alternative delivery methods such as electroporation may be less
suitable."

Dr. Marc Mansour, vice president of R&D at IVT, remarked:

"Scancell is developing an exciting DNA vaccine technology and we are delighted
to enter into this collaboration. Our DepoVaxâ„¢ technology has the potential to
better deliver DNA vaccines to draining lymph nodes to produce high levels of
immune response using conventional immunization techniques."

The Directors of the issuer accept responsibility for this announcement.

                                    -ENDS-                                     

For Further Information:

Professor Lindy Durrant       Scancell Holdings Plc  + 44 207 245 1100 
                                                                       
Adam Reynolds/Vikki Krause    Hansard Group          + 44 7515 922906  
                                                                       
Ross Andrews                  Zeus Capital           + 44 (0)161 831   
                                                     1512              

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® technology
platform. Scancell's first cancer vaccine SCIB1 is being developed for the
treatment of melanoma and will enter clinical trials in early 2010.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the cellular
immune system; the helper cell system where inflammation is stimulated at the
tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system
cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing
them with tumour antigens and re-infusing them. However, this procedure is
patient specific, time consuming and expensive. Scancell has developed its
breakthrough patent protected ImmunoBody® technology to overcome these
limitations.

An ImmunoBody® is a DNA vaccine encoding a human antibody or fusion protein
engineered to express helper cell and CTL epitopes from tumour antigens
over-expressed by cancer cells. Antibodies are ideal vectors for carrying T
cell epitopes from tumour antigens as they can effectively target dendritic
cells via their Fc receptors, allowing efficient stimulation of high avidity
and high frequency helper and CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any
tumour type and may also be of potential utility in the development of vaccines
against hepatitis, HIV and other chronic infectious diseases.

About ImmunoVaccine Technologies

ImmunoVaccine Technologies continues to strengthen its vaccine pipeline through
licensing and strategic partnering to develop therapeutic cancer and infection
disease vaccines. In 2008, Pfizer Animal Health licensed its proprietary
vaccine delivery technology for two livestock vaccines. With positive
pre-clinical safety data and recent partnerships with LIAI, NIH, Yokohoma City
University, Defence Research & Development Canada, FIT Biotech, and Immunotope
Inc. the value of Depovaxâ„¢ has been significantly enhanced. 
www.immunovaccine.com.